Keith Gottesdiener, Prime Medicine CEO
September 30, 2024 07:35 AM EDTUpdated 02:27 PM
Deals
R&D

Up­dat­ed: Prime Med­i­cine whit­tles down pipeline, signs gene edit­ing deal with Bris­tol My­ers

Lei Lei Wu

News Reporter

Prime Med­i­cine is cut­ting its pipeline, but gain­ing a part­ner.

The gene edit­ing com­pa­ny, which once boast­ed a pipeline of 18 pro­grams, is now fo­cus­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times